Bavencio

(Avelumab)

Phase 3Monoclonal antibody

Avelumab is used to treat certain types of cancer, including melanoma and a type of kidney cancer. It works by helping the body's immune system recognize and attack cancer cells.[1] Bavencio is currently being investigated across 83 indications[3], with its most advanced program in Phase 3.[1]

Bavencio is one of 1227 small molecule programs targeting Glioma. It is currently in Phase 3.

Indications

231

Total Trials

Active Trials

1,226

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

GliomaActive, not recruiting

Small Cell CarcinomaActive, not recruiting

Gestational Trophoblastic NeoplasmActive, not recruiting

ChordomaActive, not recruiting

Urinary Bladder CarcinomaActive, not recruiting

Colorectal CarcinomaActive, not recruiting

Merkel Cell Skin CancerUnknown

Esophageal Squamous Cell CarcinomaActive, not recruiting

LeiomyosarcomaActive, not recruiting

Lung CancerActive, not recruiting

GliomaPhase 1

Active, not recruiting

Small Cell CarcinomaPhase 2

Active, not recruiting

Gestational Trophoblastic NeoplasmPhase 2

Active, not recruiting

ChordomaPhase 1/Phase 2

Active, not recruiting

Urinary Bladder CarcinomaPhase 2

Active, not recruiting

Colorectal CarcinomaPhase 2

Active, not recruiting

Merkel Cell Skin CancerPreclinical

Unknown

Esophageal Squamous Cell CarcinomaPhase 2

Active, not recruiting

LeiomyosarcomaPhase 2

Active, not recruiting

Lung CancerPhase 2

Active, not recruiting

Showing 10 of 83 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Bavencio

EMD Serono

Phase 3

10 2

Tecentriq

Roche

Preclinical

36 3

Halaven

Eisai

Preclinical

38 4

Trodelvy

Gilead

Preclinical

37 5

Adriamycin

GGynecologic Oncology Group

Preclinical

87 6

MS Contin

Merck & Co.

Preclinical

2 7

Lexiscan

Astellas

Preclinical

1 8

Recentin

NNational Cancer Institute (NCI)

Preclinical

2 9

Spravato

WWim Janssens

Preclinical

2 10

Avastin

Roche

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Recruiting

Breast Cancer

NCT04360941

Phase 1Active, not recruiting

Lenvatinib

NCT05081180

Phase 1Active, not recruiting

Advanced Stage

NCT03252938

Q4 2026

Phase 1Active, not recruiting

Urothelial Carcinoma

NCT04004442

Phase 2Active, not recruiting

Endometrial Cancer

NCT02912572

Phase 1Active, not recruiting

Solid Tumors

NCT05222932

Clinical

Trials by Indication[1]

Bladder Cancer9 trials

Bladder PREserVation by RadioTherapy and Immunotherapy in BCG Unresponsive Non-muscle Invasive Bladder Cancer

Unknown status·IInstitut Paoli-Calmettes·Phase 2·NCT03950362·67 enrolled

Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer

Completed·MMayo Clinic·Phase 2·NCT03617913·2 enrolled

Avelumab and Radiation in Muscle-Invasive Bladder Cancer

Terminated·—·Phase 2·NCT03747419·14 enrolled

Show 6 more trials

Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Cancer

Completed·UUniversity of Oklahoma·Phase 1/2·NCT03892642·18 enrolled

KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer

Terminated·KKyowa Kirin, Inc.·Phase 1·NCT03915405·16 enrolled

Avelumab as Neoadjuvant Therapy in Subjects With Urothelial Muscle Invasive Bladder Cancers (AURA Trial)

Completed·JJules Bordet Institute·Phase 2·NCT03674424·137 enrolled

A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer

Terminated·—·Phase 1/2·NCT03498196·1 enrolled

Drug Screening Using IMD in Bladder Cancer

Unknown status·—·Phase 1·NCT06204614·18 enrolled

Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer

Withdrawn·VVA Office of Research and Development·Phase 1/2·NCT05687721

Breast Cancer9 trials

QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy

Withdrawn·IImmunityBio, Inc.·Phase 1/2·NCT03175666

Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

Recruiting·LLaura Huppert, MD, BA·Phase 2·NCT03971409·150 enrolled

The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer

Active, not recruiting·—·Phase 2·NCT03414658·100 enrolled

Show 6 more trials

Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer

Active, not recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT03573648·33 enrolled

QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine

Withdrawn·IImmunityBio, Inc.·Phase 2·NCT03554109

PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer

Recruiting·RRoyal Marsden NHS Foundation Trust·Phase 1·NCT04360941·45 enrolled

Avelumab or Hydroxychloroquine with or Without Palbociclib to Eliminate Dormant Breast Cancer

Recruiting·—·Phase 2·NCT04841148·96 enrolled

QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.

Terminated·IImmunityBio, Inc.·Phase 1/2·NCT03387085·9 enrolled

A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study

Active, not recruiting·OOncolytics Biotech·Phase 2·NCT04215146·48 enrolled

Non-Small Cell Lung Cancer7 trials

QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer

Withdrawn·IImmunityBio, Inc.·Phase 2·NCT03574649

SBRT Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC)

Terminated·AAndrew Sharabi·Phase 1/2·NCT03050554·2 enrolled

A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy

Completed·DDebiopharm International SA·Phase 1·NCT03270176·54 enrolled

Show 4 more trials

QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors

Withdrawn·IImmunityBio, Inc.·Phase 1/2·NCT03169738

Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200)

Completed· EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.·Phase 3·NCT02395172·792 enrolled

A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)

Terminated· Pfizer logo

Pfizer·Phase 2·NCT03472560·61 enrolled

Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)

Completed·SSWOG Cancer Research Network·Phase 2·NCT04173507·47 enrolled

Merkel Cell Carcinoma7 trials

Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04792073·18 enrolled

Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma

Terminated·FFred Hutchinson Cancer Center·Phase 1/2·NCT02584829·8 enrolled

Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma

Active, not recruiting·MMelanoma and Skin Cancer Trials Limited·Phase 2·NCT04291885·122 enrolled

Show 4 more trials

QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy

Terminated·IImmunityBio, Inc.·Phase 2·NCT03853317·9 enrolled

Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma

Unknown status·KKartos Therapeutics, Inc.·Phase 1/2·NCT03787602·115 enrolled

QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy

Withdrawn·IImmunityBio, Inc.·Phase 1/2·NCT03167164

Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)

Completed· EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.·Phase 2·NCT02155647·204 enrolled

Urothelial Carcinoma7 trials

A NON-INTERVENTIONAL STUDY ON AVELUMAB USE IN PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA

Completed· Pfizer logo

Pfizer··NCT04822350·599 enrolled

Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma

Active, not recruiting·EEmory University·Phase 2·NCT04848519·6 enrolled

A Study to Learn About the Study Medicine (Avelumab) in Japanese Patients With Urothelial Carcinoma That Has Spread

Completed· Merck & Co. logo

Merck & Co.··NCT05431777·79 enrolled

Show 4 more trials

A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)

Active, not recruiting· EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.·Phase 2·NCT05327530·256 enrolled

Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma

Completed·MMassachusetts General Hospital·Phase 2·NCT04701918·9 enrolled

Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma

Terminated·—·Phase 2·NCT04322643·4 enrolled

Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma

Active, not recruiting·UUniversity of Oklahoma·Phase 1·NCT04004442·19 enrolled

96 more indications

Ovarian Cancer6 trials

A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200)

Completed· Pfizer logo

Pfizer·Phase 3·NCT02580058·566 enrolled

Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer

Completed·SSyndax Pharmaceuticals·Phase 1/2·NCT02915523·140 enrolled

Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer

Completed· EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.·Phase 1·NCT03704467·3 enrolled

Show 3 more trials

Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy

Completed· Gilead logo

Gilead·Phase 1·NCT03558139·34 enrolled

Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)

Terminated· Pfizer logo

Pfizer·Phase 3·NCT02718417·998 enrolled

Anti-PD-L1 and SAbR for Ovarian Cancer

Terminated·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT03312114·5 enrolled

Metastatic Colorectal Cancer6 trials

Avelumab Plus Cetuximab in Pre-treated RAS Wild Type Metastatic Colorectal Cancer

Completed·UUniversity of Campania Luigi Vanvitelli·Phase 2·NCT04561336·77 enrolled

Avelumab Plus Autologous Dendritic Cell Vaccine in Pre-treated Metastatic Colorectal Cancer Patients

Completed·GGrupo Espanol Multidisciplinario del Cancer Digestivo·Phase 1/2·NCT03152565·28 enrolled

Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT03050814·30 enrolled

Show 3 more trials

Avelumab and Cetuximab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer - The Phase II AVETUX-CRC Trial.

Completed·AAIO-Studien-gGmbH·Phase 2·NCT03174405·43 enrolled

Avelumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer

Unknown status·—·Phase 2·NCT03150706·33 enrolled

AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients

Completed·GGruppo Oncologico del Nord-Ovest·Phase 2·NCT04513951·62 enrolled

Advanced Urothelial Cancer5 trials

Avelumab as Single Agent in Metastatic or Locally Advanced Urothelial Cancer in Patients Unfit for Cisplatin. The ARIES Study

Completed·CConsorzio Oncotech·Phase 2·NCT03891238·67 enrolled

Chemotherapy and Sequential Immunotherapy for Locally Advanced Urothelial Cancer

Recruiting·EErasmus Medical Center·Phase 2·NCT05600127·64 enrolled

Comparing 3 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab in Advanced Urothelial Cancer

Recruiting·QQueen Mary University of London·Phase 2·NCT06892860·320 enrolled

Show 2 more trials

A Study to Learn About the Study Medicine (Called Avelumab) in People With Advanced Urothelial Cancer After Chemotherapy

Completed· Merck & Co. logo

Merck & Co.··NCT05366725·106 enrolled

Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder)

Withdrawn· EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.·Phase 2·NCT06424717

Renal Cell Carcinoma5 trials

To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell Carcinoma

Completed· Pfizer logo

Pfizer··NCT04682587·481 enrolled

Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04068831·18 enrolled

Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC)

Completed·UUniversity of Utah·Phase 1·NCT03200587·12 enrolled

Show 2 more trials

Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma

Unknown status·CConsorzio Oncotech·Phase 2·NCT04698213·75 enrolled

Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma

Withdrawn·GGuru Sonpavde·Phase 2·NCT03035630

Lymphoma4 trials

Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma[AVENT STUDY]

Unknown status·SSamsung Medical Center·Phase 2·NCT03439501·21 enrolled

Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window Study

Unknown status·UUniversity College, London·Phase 2·NCT03617666·49 enrolled

Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS)

Terminated· Pfizer logo

Pfizer·Phase 1·NCT02603419·34 enrolled

Show 1 more trial

QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL

Withdrawn·IImmunityBio, Inc.·Phase 1/2·NCT03169790

Glioblastoma4 trials

Clinical Trial on the Combination of Avelumab and Axitinib for the Treatment of Patients With Recurrent Glioblastoma

Completed·UUniversitair Ziekenhuis Brussel·Phase 2·NCT03291314·52 enrolled

Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma

Completed·IIcahn School of Medicine at Mount Sinai·Phase 1·NCT03341806·13 enrolled

Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma

Completed·NNYU Langone Health·Phase 2·NCT02968940·6 enrolled

Show 1 more trial

VXM01 Plus Avelumab Combination Study in Progressive Glioblastoma

Unknown status·VVaximm GmbH·Phase 1/2·NCT03750071·30 enrolled

Metastatic Urothelial Cancer4 trials

A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)

Completed· Pfizer logo

Pfizer·Phase 3·NCT02603432·700 enrolled

A Study of Avelumab in Real-World Treatment for Patients With Advanced or Metastatic Urothelial Cancer

Terminated· Pfizer logo

Pfizer··NCT05568407·19 enrolled

Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT03744793·18 enrolled

Show 1 more trial

Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT05092958·654 enrolled

Pancreatic Cancer4 trials

QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

Terminated·IImmunityBio, Inc.·Phase 1/2·NCT03329248·6 enrolled

QUILT-3.088: NANT Pancreatic Cancer Vaccine

Withdrawn·IImmunityBio, Inc.·Phase 2·NCT03563144

A Trial of PEGPH20 in Combination With Avelumab in Chemotherapy Resistant Pancreatic Cancer

Terminated·PPH Research, S.L.·Phase 1·NCT03481920·7 enrolled

Show 1 more trial

QUILT-3.080: NANT Pancreatic Cancer Vaccine

Terminated·IImmunityBio, Inc.·Phase 1/2·NCT03586869·3 enrolled

Advanced Solid Tumors3 trials

A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab

Completed·PPromontory Therapeutics Inc.·Phase 1/2·NCT03409458·68 enrolled

A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors

Terminated·LLeap Therapeutics, Inc.·Phase 1·NCT03861403·10 enrolled

FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Terminated·FFate Therapeutics·Phase 1·NCT04551885·12 enrolled

Urothelial Cancer3 trials

QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Withdrawn·IImmunityBio, Inc.·Phase 1/2·NCT03197571

Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

Recruiting· Gilead logo

Gilead·Phase 2·NCT03547973·827 enrolled

A Combination of Avelumab and Taxane (AVETAX) for Urothelial Cancer

Completed·YYousef Zakharia·Phase 1·NCT03575013·21 enrolled

Gastric Cancer3 trials

GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer

Completed·GGenome & Company·Phase 2·NCT05419362·42 enrolled

Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)

Completed· EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.·Phase 3·NCT02625623·371 enrolled

Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)

Completed· EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.·Phase 3·NCT02625610·499 enrolled

Radiotherapy3 trials

Bioimmunoradiotherapy (Cetuximab/RT/Avelumab)

Completed·TThe Netherlands Cancer Institute·Phase 1·NCT02938273·10 enrolled

UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients

Completed·MMegan Daly, MD·Phase 1·NCT03158883·8 enrolled

Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH)

Active, not recruiting·GGroupe Oncologie Radiotherapie Tete et Cou·Phase 3·NCT02999087·707 enrolled

Treatment3 trials

An Observational Chart Review Study To Describe The Real-World Outcomes And Use Of Avelumab In Combination With Axitinib For Treatment Of Patients With aRCC In The UK

Completed· Pfizer logo

Pfizer··NCT05394493·130 enrolled

Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy

Active, not recruiting·AAlliance for Clinical Trials in Oncology·Phase 3·NCT04637594·3 enrolled

JAVEMACS: Japan AVElumab Maintenance And Continuous Treatment Study

Active, not recruiting· Merck & Co. logo

Merck & Co.··NCT06412848·360 enrolled

Endometrial Cancer3 trials

Carboplatin, Paclitaxel With or Without Avelumab in Advanced or Recurrent Endometrial Cancer

Unknown status·NNational Cancer Institute, Naples·Phase 2·NCT03503786·125 enrolled

Avelumab and M1774 in ARID1A-mutated Endometrial Cancer

Recruiting·—·Phase 2·NCT06518564·25 enrolled

Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer

Active, not recruiting·—·Phase 2·NCT02912572·106 enrolled

Colorectal Cancer3 trials

A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer

Completed·EEffector Therapeutics·Phase 2·NCT03258398·56 enrolled

QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine

Terminated·IImmunityBio, Inc.·Phase 1/2·NCT03563157·2 enrolled

QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC

Withdrawn·IImmunityBio, Inc.·Phase 1/2·NCT03169777

Acute Myeloid Leukemia3 trials

Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)

Withdrawn·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT03699384

OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT03390296·50 enrolled

Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT02953561·19 enrolled

Diffuse Large B-Cell Lymphoma2 trials

Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

Terminated· Pfizer logo

Pfizer·Phase 3·NCT02951156·29 enrolled

Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma

Completed·—·Phase 1·NCT03440567·16 enrolled

Head and Neck Cancer2 trials

EACH: Evaluating Avelumab in Combination With Cetuximab in Head and Neck Cancer

Active, not recruiting·UUniversity College, London·Phase 2·NCT03494322·130 enrolled

Intratumoral Microdosing of TAK-981 in Head and Neck Cancer

Completed·PPresage Biosciences·Phase 1·NCT04065555·12 enrolled

Immune Checkpoint Inhibitor2 trials

Immune Checkpoint Inhibitor In High Risk Oral Premalignant Lesions

Unknown status·AAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia·Phase 2·NCT04504552·240 enrolled

Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)

Active, not recruiting· EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.·Phase 1·NCT05396833·120 enrolled

Neuroendocrine Carcinoma2 trials

Phase II Study of Avelumab in Metastatic Gastronetro-pancreatic （GEP） Neuroendocrine Carcinoma （NEC, WHO Grade 3） as Second-line Treatment After Failing to Etoposide+Cisplatin: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes

Completed·SSamsung Medical Center·Phase 2·NCT03147404·14 enrolled

Avelumab Treatment in Patients With Neuroendocrine Carcinomas (NEC G3) Progressive After Chemotherapy

Completed·JJohannes Gutenberg University Mainz·Phase 2·NCT03352934·60 enrolled

Gemcitabine2 trials

Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT03717155·43 enrolled

Avelumab/Gemcitabine in Sarcomatoid RCC

Terminated·—·Phase 1·NCT03483883·6 enrolled

First Line Therapy2 trials

Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART2)

Completed· Merck & Co. logo

Merck & Co.··NCT05650164·171 enrolled

Current Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART)

Completed· Pfizer logo

Pfizer··NCT05012865·48 enrolled

Advanced2 trials

Avelumab, Palbociclib and Axitinib in Advanced RCC

Withdrawn·—·Phase 2·NCT05176288

A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)

Completed· Pfizer logo

Pfizer·Phase 1·NCT03289533·22 enrolled

Hepatocellular Carcinoma2 trials

Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma

Terminated·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT05249569·1 enrolled

Phase II Study of Avelumab in Patients With Advanced Hepatocellular Carcinoma After Prior Sorafenib Treatment

Completed·SSeoul National University Hospital·Phase 2·NCT03389126·30 enrolled

Esophageal Adenocarcinoma2 trials

Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas

Completed·AAshwin Somasundaram·Phase 2·NCT03783936·18 enrolled

Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal Adenocarcinoma

Unknown status·PP. C. Thuss-Patience·Phase 2·NCT03966118·59 enrolled

Locally-advanced Rectal Cancer2 trials

Immunotherapy In Locally Advanced Rectal Cancer

Completed·GGruppo Oncologico del Nord-Ovest·Phase 2·NCT03854799·101 enrolled

Avelumab With Chemoradiation in Locally Advanced Rectal Cancer

Completed·PPeter MacCallum Cancer Centre, Australia·Phase 2·NCT03299660·37 enrolled

Advanced Malignancies2 trials

A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)

Terminated· Pfizer logo

Pfizer·Phase 1/2·NCT02554812·409 enrolled

Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT03217747·173 enrolled

Squamous Cell Carcinoma2 trials

Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)

Terminated· Pfizer logo

Pfizer·Phase 3·NCT02952586·697 enrolled

QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed

Terminated·IImmunityBio, Inc.·Phase 1/2·NCT03387111·4 enrolled

Renal Cell Cancer2 trials

A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)

Completed· Pfizer logo

Pfizer·Phase 3·NCT02684006·886 enrolled

A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100)

Completed· Pfizer logo

Pfizer·Phase 1·NCT02493751·55 enrolled

Head and Neck Squamous Cell Carcinoma2 trials

QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Withdrawn·IImmunityBio, Inc.·Phase 1/2·NCT03169764

Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Active, not recruiting·KKathryn Gold·Phase 1·NCT03498378·24 enrolled

Metastatic2 trials

A Study Combining Eribulin Mesylate With Avelumab in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients

Terminated·—·Phase 1·NCT03502681·6 enrolled

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

Active, not recruiting·UUniversity of Southern California·Phase 1·NCT04387084·10 enrolled

Phase IB2 trials

A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination With M9241(NHS-IL12) (JAVELIN IL-12)

Terminated· EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.·Phase 1·NCT02994953·52 enrolled

Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers

Active, not recruiting·TTransgene·Phase 1/2·NCT03260023·143 enrolled

Chemotherapy2 trials

Avelumab With Decitabine as First Line for AML Treatment of Patients With AML, Who Are Unfit for Intensive Chemotherapy

Terminated·MMilton S. Hershey Medical Center·Phase 1·NCT03395873·7 enrolled

Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer

Completed·FFederation Francophone de Cancerologie Digestive·Phase 2·NCT03186326·132 enrolled

Melanoma1 trial

QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy

Withdrawn·IImmunityBio, Inc.·Phase 1/2·NCT03167177

Squamous Cell Cancer1 trial

Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer

Active, not recruiting·AAlliance for Clinical Trials in Oncology·Phase 2·NCT03944941·60 enrolled

Multiple Myeloma1 trial

Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT03910439·4 enrolled

Triple-Negative Breast Cancer1 trial

A Proof of Concept Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer

Withdrawn·TThe Christie NHS Foundation Trust·Phase 2·NCT04188119

Unresectable Solid Tumor1 trial

Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT04266912·23 enrolled

Unresectable Cancer1 trial

Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy

Completed·NNKGen Biotech, Inc.·Phase 1·NCT03941262·27 enrolled

Solid Tumors1 trial

Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1

Active, not recruiting·TTILT Biotherapeutics Ltd.·Phase 1·NCT05222932·15 enrolled

Advanced Cancers1 trial

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT04902040·19 enrolled

Combination Therapy1 trial

A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors

Active, not recruiting·EExelixis·Phase 1·NCT03845166·325 enrolled

Unresectable1 trial

Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer

Terminated·FFred Hutchinson Cancer Center·Phase 1/2·NCT03747484·7 enrolled

Prostate Cancer1 trial

PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer

Completed·—·Phase 2·NCT03179410·15 enrolled

Metastatic Cancer1 trial

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Recruiting·AAulos Bioscience, Inc.·Phase 1/2·NCT05267626·159 enrolled

Adjuvant Treatment1 trial

Avelumab Plus 5-FU Based Chemotherapy as Adjuvant Treatment for Stage 3 MSI-High or POLE Mutant Colon Cancer

Terminated·RRoyal Marsden NHS Foundation Trust·Phase 3·NCT03827044·30 enrolled

Chronic Myelogenous Leukemia1 trial

Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR (ACTIW)

Unknown status·VVersailles Hospital·Phase 1/2·NCT02767063·100 enrolled

Meningioma1 trial

Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma

Terminated·WWashington University School of Medicine·Phase 1·NCT03267836·9 enrolled

Patients With Solid Tumors1 trial

GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy

Completed·GGenome & Company·Phase 1·NCT04601402·11 enrolled

Anal Carcinoma1 trial

Cetuximab + Avelumab or Avelumab Alone for Unresectable, Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (SCCAC) Progressed After at Least One Line of Systemic Treatment (CARACAS)

Unknown status·GGruppo Oncologico del Nord-Ovest·Phase 2·NCT03944252·54 enrolled

Acute Lymphoblastic Leukemia1 trial

CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy

Unknown status·UUniversity of Campania Luigi Vanvitelli·Phase 2·NCT05291156·173 enrolled

Adjuvant1 trial

Adjuvant Avelumab in Merkel Cell Cancer

Active, not recruiting·UUniversity of Washington·Phase 3·NCT03271372·101 enrolled

Survival1 trial

Survival Prolongation by Rationale Innovative Genomics

Terminated·WWorldwide Innovative Network Association·Phase 1/2·NCT03386929·15 enrolled

Renal Carcinoma1 trial

Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT04150562·2 enrolled

Intestinal Cancer1 trial

Epigenetic Modulation of the immunE Response in GastrointEstinal Cancers (EMERGE)

Unknown status·RRoyal Marsden NHS Foundation Trust·Phase 2·NCT03812796·75 enrolled

Neoadjuvant1 trial

Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC

Unknown status·TThe Netherlands Cancer Institute·Phase 2·NCT03341845·40 enrolled

Chordoma1 trial

QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.

Withdrawn·IImmunityBio, Inc.·Phase 1/2·NCT03647423

Lenvatinib1 trial

Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors

Active, not recruiting· EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.·Phase 1·NCT05081180·17 enrolled

EGFR Mutation1 trial

Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)

Terminated· Pfizer logo

Pfizer·Phase 1/2·NCT02349633·65 enrolled

Leptomeningeal Disease1 trial

Avelumab With Radiotherapy in Patients With Leptomeningeal Disease

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT03719768·16 enrolled

Osteosarcoma1 trial

A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma

Completed·SSt. Jude Children's Research Hospital·Phase 2·NCT03006848·19 enrolled

Advanced Stage1 trial

Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors

Active, not recruiting·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 1·NCT03252938·83 enrolled

Cancer1 trial

Avelumab With Valproic Acid in Virus-associated Cancer

Completed·AAHS Cancer Control Alberta·Phase 2·NCT03357757·39 enrolled

Tumor Microenvironment1 trial

Targeting the Tumor Microenvironment in R/M SCCHN

Unknown status·GGruppo Oncologico del Nord-Ovest·Phase 1/2·NCT03844763·71 enrolled

Penile Carcinoma1 trial

Maintenance Avelumab Immunotherapy in Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma

Unknown status·—·Phase 2·NCT03774901·32 enrolled

Esophageal Squamous Cell Carcinoma1 trial

The Ave-CRT Study for Newly Diagnosed Metastatic Esophageal Squamous Cell Carcinoma

Unknown status·NNational Taiwan University Hospital·Phase 2·NCT03800953·26 enrolled

Metastatic Nasopharyngeal Cancer1 trial

Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer

Terminated·—·Phase 2·NCT02875613·6 enrolled

Locally Advanced1 trial

A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors

Terminated· Pfizer logo

Pfizer·Phase 1/2·NCT03637491·36 enrolled

Microsatellite Stable1 trial

Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer

Unknown status·CCliniques universitaires Saint-Luc- Université Catholique de Louvain·Phase 2·NCT03608046·59 enrolled

Efficacy1 trial

Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)

Terminated· Pfizer logo

Pfizer·Phase 1/2·NCT02584634·43 enrolled

Testicular Germ Cell Cancer1 trial

Avelumab in Refractory Testicular Germ Cell Cancer.

Completed·NNational Cancer Institute, Slovakia·Phase 2·NCT03403777·8 enrolled

Papilloma1 trial

Avelumab for People With Recurrent Respiratory Papillomatosis

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT02859454·13 enrolled

CRC1 trial

FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC

Completed·LLudwig-Maximilians - University of Munich·Phase 2·NCT05217069·57 enrolled

Bladder Carcinoma1 trial

First-line Gemcitabine/Cisplatin +/- Avelumab in Locally Advanced or Metastatic Bladder Carcinoma

Terminated·UUniversity Hospital, Bordeaux·Phase 2·NCT03324282·65 enrolled

Angiosarcoma1 trial

Paclitaxel-Avelumab for Angiosarcoma

Unknown status·SSung Yong Oh·Phase 2·NCT03512834·32 enrolled

Adenocarcinoma1 trial

Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma

Terminated·VVanderbilt-Ingram Cancer Center·Phase 2·NCT03000179·8 enrolled

Relapsed/Refractory1 trial

Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT03905135·8 enrolled

Adenoid Cystic Carcinoma1 trial

Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT03990571·40 enrolled

Dendritic Cell1 trial

Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors

Unknown status·UUniversitair Ziekenhuis Brussel·Phase 2·NCT04571632·36 enrolled

Methotrexate1 trial

Avelumab and Methotrexate in in Low-risk Gestational Trophoblastic Neoplasias as First Line Treatment

Recruiting·HHospices Civils de Lyon·Phase 1/2·NCT04396223·26 enrolled

First-line1 trial

Avelumab in First-line NSCLC (JAVELIN Lung 100)

Completed· EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.·Phase 3·NCT02576574·1,214 enrolled

Leiomyosarcoma1 trial

Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery

Terminated·FFred Hutchinson Cancer Center·Phase 1/2·NCT03074318·35 enrolled

Clinical Trial1 trial

ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling

Recruiting·UUlrik Lassen·Phase 2·NCT04341181·300 enrolled

Metastatic Sarcoma1 trial

Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT04242238·32 enrolled

Cervical Cancer1 trial

Avelumab With Axitinib in Persistent or Recurrent Cervical Cancer After Platinum-based Chemotherapy

Completed·TThe University of Hong Kong·N/A·NCT03826589·23 enrolled

NPC1 trial

NPC - AXEL Study : Axitinib-Avelumab

Completed·—·Phase 2·NCT04562441·13 enrolled

Pediatric Cancer1 trial

Phase I/II Study of Avelumab in Pediatric Cancer Participants

Terminated· EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.·Phase 1·NCT03451825·21 enrolled

Locally Advanced Solid Tumor1 trial

Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)

Completed· EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.·Phase 1·NCT01772004·1,756 enrolled

DLBCL1 trial

Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients With Diffuse DLBCL: The AvR-CHOP Study

Active, not recruiting·AAustin Health·Phase 1·NCT03244176·28 enrolled

Glioblastoma Multiforme1 trial

Avelumab in Patients With Newly Diagnosed Glioblastoma Multiforme

Completed·CClinique Neuro-Outaouais·Phase 2·NCT03047473·38 enrolled

Advanced Solid Tumor1 trial

K-Basket, Avelumab, Biomarker-driven, Advanced Solid Tumor

Unknown status·YYonsei University·Phase 2·NCT03491345·60 enrolled

NEC1 trial

Avelumab in G3 NEC

Completed·SSunnybrook Health Sciences Centre·Phase 1/2·NCT03278405·10 enrolled

Malignant Mesothelioma1 trial

Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT03399552·15 enrolled

ES-SCLC1 trial

Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )

Terminated·AAriceum Therapeutics GmbH·Phase 1/2·NCT06939036·2 enrolled

Follicular Lymphoma1 trial

Rituximab + Immunotherapy in Follicular Lymphoma

Terminated·—·Phase 1·NCT03636503·24 enrolled

Unspecified3 trials

SOGUG-AVELUMAB_RWD

Completed·SSpanish Oncology Genito-Urinary Group··NCT05700344·125 enrolled

Avelumab in G2-3 NET

Completed·SSunnybrook Health Sciences Centre·Phase 2·NCT03278379·17 enrolled

Study of Avelumab-M3814 Combinations

Completed· EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.·Phase 1·NCT03724890·57 enrolled

Regulatory

FDA Approval Timeline[4]

Mar 23, 2017

BAVENCIO

BLA BLA761049

Sources

References

[1]
ClinicalTrials.gov — 231 trial records for Avelumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Avelumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Avelumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (BLA BLA761049). U.S. Food & Drug Administration.
[5]
SEC EDGAR — EMD Serono company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Programmed Cell Death 1 Ligand 1 Other[2]
Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: EMD Serono